C2,5′-disubstituted and N 6 ,...

Details C2,5′-disubstituted and N 6 ,... C2,5′-disubstituted and N 6 ,...

2006-08-01

2006-08-01

Crane, L. E. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S027300, C536S027620, C536S027630

Reexamination Certificate

active

07084127

ABSTRACT:
The present invention concerns novel C2,5′-disubstituted and N6′,C2,5′-trisubstituted adenosine derivatives and their different uses. These adenosine derivatives were found to be potent adenosine receptor agonists and thus are of a therapeutic value in the treatment and prophylaxis of diseases and disorders affected by adenosine receptor agonists.

REFERENCES:
patent: 4357324 (1982-11-01), Montgomery et al.
patent: 5189027 (1993-02-01), Miyashita et al.
patent: 5278150 (1994-01-01), Olsson et al.
patent: 5589467 (1996-12-01), Lau et al.
patent: 5998388 (1999-12-01), Ellis et al.
patent: 5998423 (1999-12-01), Manneth et al.
patent: 6407076 (2002-06-01), Box et al.
patent: 6576620 (2003-06-01), Belardinelli et al.
patent: 6605597 (2003-08-01), Zablocki et al.
patent: WO 97/33591 (1997-09-01), None
patent: WO 98/15276 (1998-04-01), None
patent: WO 99/24450 (1999-05-01), None
patent: WO 99/38877 (1999-08-01), None
patent: WO 99/38877 (1999-08-01), None
patent: WO 00/23457 (2000-04-01), None
patent: WO 00/72799 (2000-12-01), None
(R)van Tilburg et al., “N6,5′-O-Disubstituted Adenosine Derivatives as Partial Agonists for the Human Adenosine A3 Receptor,” Journal of Medicinal Chemistry, 42(8), 1393-1400 (1999); Web published Mar. 31, 1999.
van Tilburg et al., “N6,5'-Disubstituted Adenosine Derivatives as Partial Agonists for the Humans Adenosine A3Receptor,”Journal of Medicinal Chemistry, 42(8), 1393-1400 (1999); Web published Mar. 31, 1999.
Homma, Hiroshi et al “Nucleosides and Nucleotides. 112.2-(1-Hexyn-1-y1)adenosine-5′-uranomides: A New Entry of Selective A2Adenosine Receptor Agonists with Potent Antihypertensive Activity” J.Med. Chem. (1992) vol. 35 pp.: 2881-2890.
Matsuda, Akira et al “Nucleosides and Nucleotides. 103. 2-Alkynyladenosines: A Novel Class of Selective Adenosine A2Receptor Agonists with Potent Antihypertensive Effects” J. Med. Chem. (1992) vol. 35 pp.: 241-252 (Jan. 24, 1992).
Niiya, Kazunori “2-(N′-Alkylidenehydrazino)adenosines: Potent and Selective Coronary Vasodilators” J. Med. Chem. (1992) vol. 35 pp.: 4557-4561.
Van Der Wenden, Eleonora M. et al “5′-Substituted Adenosine Analogs as New High-Affinity Partial Agonist for the Adenosine A1Receptor” J. Med. Chem (1998) vol. 41 pp.: 102-108.
Vittori, Sauro et al “2-Alkenyl and 2-Alkyl Derivatives of Adenosine and Adenosine-5'-N-Ethyluronamide: Different Affinity and Selectivity ofE-andZ-Diastereomers at A2AAdenosine Receptors” J.Med. Chem (1996) vol. 39 pp.: 4211-4217.
Bruns, R., “Adenosine Receptor Activation in Human Fibroblasts: Nucleoside Agonists and Antagonists”, Can. J. Physiol. Pharmacol. 1980, 58: 673-691.
Chiang, et al., “S-Adenosyl-L-hemocysteine Hydrolase: Analogues ofS-Adenosyl-L-homocysteine as Potential Inhibitors”, Molecular Pharmacology. 1977, vol. 13, 939-947.
Cristalli, et al., “2-Alkynel Derivatives of Adenosine and Adenosine-5'-N-ethyluronamide as Selective Agonists at A2Adenosine Receptors”, J. Med. Chem. 1992, vol. 35, 2363-2368.
Cristalli, et al., “Characterization of Potent Ligands at Human Recombinant Adenosine Receptors”, Drug Development Research. 1998, vol. 45, 176-181.
Daly, et al., “Agonist Activity of 2- and 5′-substituted Adenosine Analogs and TheirN6-Cycloalkyl Derivatives at A1-and A2-Adenosine Receptors Coupled to Adenylate Cyclase”, Biochemical Pharmacology, vol. 43 No. 5, 1089-1093.
Gallo-Rodriguez, et al., “Structure-Activity Relationships ofN6-Benzyladenosine-5'-uronamides as A3-Selective Adenosine Agonists”, J. Med. Chem. 1994, vol. 37, 636-646. Published in ACS ABstracts on Jan. 15, 1994.
Hutchinson, et al., “2-(Arylalkylamino)adenosine-5′-uronamides: A New Class of Highly Selective Adenosine A2Receptor Ligands”, J. Med. Chem. 1990, vol. 33, 1919-1924.
Klotz, et al., “2-Substitutedn-ethylcarboxamidoadenosine Derivatives as High-affinity Agonists at Human A3Adenosine Receptors”, Naunyn-Schmiedeberg's Arch Pharmacol. 1999, vol. 360, 103-108. Published online Jul. 13, 1999.
Roelen, et al., “N6, C8-Disubstituted Adenosine Derivatives as Partial Agonists for Adenosine A1Receptors”, J. Med. Chem. 1996, vol. 39, 1463-1471. (Published in ACS Abstracts on Feb. 15, 1996).
Van Tilburg, et al., “2,5'-Disubstituted Adenosine Derivatives: Evaluation of Selectivity and Efficacy for the Adenosine A1, A2Aand A3Receptor”, J. Med. Chem. 2002, vol. 45, 420-429. WEB published on Dec. 19, 2001.
Van Tilburg, et al., “6'-O-Alkyl Ethers ofN,2-Substituted Adenosine Derivatives: Partial Agonists for the Adenosine A1and A3Receptor”, J. Med. Chem. 2001, vol. 44, 2966-2975. WEB Published on Jul. 26, 2001.
Van Tilburg, et al., “N6,5'-Disubstituted Adenosine Derivatives as Partial Agonists for the Human Adenosine A3Receptor”, J. Med. Chem. Apr. 22, 1999; vol. 42(8), 1393-1400.
Volpini, et al., “Synthesis of Di- and Tri-Substituted Adenosine Derivatives and Their ffinities at Human Adenosine Receptor Subtypes”, Nucleosides & Nucleotides. 1999, vol. 18(11&12), 2511-2520.

Affiliated with

Also associated with

Rating

C2,5′-disubstituted and N 6 ,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with C2,5′-disubstituted and N 6 ,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C2,5′-disubstituted and N 6 ,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3620418